Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers [Phase 1]
Phase 1 trial assessing cabiralizumab with nivolumab in selected advanced cancers has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) [Phase 1, Phase 2]
Clinical trial update for QL1706 plus lenvatinib in advanced renal cell carcinoma (Phase 1/2) with unknown status.
-
CLINICAL_TRIALS trial_result · 2022-02-24Clinical Trial Update: Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma [Phase 2]
Phase 2 study of TAK-228 (sapanisertib) in patients with previously treated metastatic renal cell carcinoma has completed, with results post…
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Clinical trial update for metastatic/advanced renal cell carcinoma treated with sunitinib/axitinib; study completed with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) [Phase 2]
Phase II trial investigating sequential single-agent nivolumab followed by combination ipilimumab plus nivolumab in metastatic or unresectab…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial update reports results for the combination of ibrutinib and nivolumab in patients with previously treated metasta…
-
CLINICAL_TRIALS trial_result · 2022-02-03Clinical Trial Update: Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC) [Phase 2]
This update reports Phase 2 results from a neoadjuvant trial of axitinib in locally advanced renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2022-02-01Clinical Trial Update: Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) [Phase 2]
Phase 2 trial evaluating everolimus and bevacizumab in advanced non-clear cell renal cell carcinoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating cytokine-induced killer cells for metastatic urogenital tumors (bladder and renal cancer) is ongoing b…
-
CLINICAL_TRIALS trial_result · 2021-12-29Clinical Trial Update: A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC [Phase 2]
Phase 2 study evaluating safety and efficacy of tislelizumab plus axitinib as neoadjuvant therapy for clear cell renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2021-12-28Clinical Trial Update: Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) [Phase 3]
Phase 3 trial assessing pembrolizumab as adjuvant therapy after nephrectomy in renal cell carcinoma has completed, with results posted in 20…
-
CLINICAL_TRIALS trial_result · 2021-12-23Clinical Trial Update: Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 [Phase 2]
Phase 2 clinical trial update for second-line pazopanib in renal cell carcinoma.
-
FDA approval · 2021-12-13FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals Corporation. Pazopanib is used …
-
CLINICAL_TRIALS trial_result · 2021-12-13Clinical Trial Update: REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Clinical trial update reporting complete responses to sunitinib in Spanish patients with metastatic renal cell carcinoma; results posted fro…
-
CLINICAL_TRIALS trial_result · 2021-12-06Clinical Trial Update: Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC [Phase 1, Phase 2]
Phase 1/2 study of tivozanib in combination with nivolumab in renal cell carcinoma has completed.
-
FDA approval · 2021-12-06FDA Approved: SUNITINIB MALATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved a generic version of sunitinib malate submitted by Mylan Pharmaceuticals Inc., for use in cancer indications shared with the re…
-
CLINICAL_TRIALS trial_result · 2021-11-29Clinical Trial Update: Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial evaluating various sunitinib schedules in kidney cancer (renal cell carcinoma), status currently unknown.
-
CLINICAL_TRIALS trial_result · 2021-11-18Clinical Trial Update: Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial exploring the combination of anlotinib and everolimus as first-line treatment for advanced non-clear cell renal cell …
-
CLINICAL_TRIALS trial_result · 2021-11-05Clinical Trial Update: Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment
A completed clinical trial evaluating fatigue- and hand-foot syndrome-related quality of life in patients with metastatic renal cell carcino…
-
CLINICAL_TRIALS trial_result · 2021-10-22Clinical Trial Update: Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies [Phase 3]
Phase 3 trial update on systemic treatments for bone metastases in metastatic renal cell carcinoma patients treated with targeted therapies;…
-
FDA approval · 2021-10-18FDA Approved: EVEROLIMUS — Original Application (Par Health USA, LLC)
FDA approved Par Health USA, LLC's Original Application for EVEROLIMUS (a generic version of everolimus). The approval enables the generic p…
-
CLINICAL_TRIALS trial_result · 2021-10-14Clinical Trial Update: A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer [Phase 4]
Phase 4 trial updating safety of nivolumab plus ipilimumab in previously untreated advanced or metastatic renal cell carcinoma; results post…
-
CLINICAL_TRIALS trial_result · 2021-10-06Clinical Trial Update: Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen [Phase 2]
A Phase 2 clinical trial evaluating nivolumab in patients with metastatic renal cell carcinoma who progressed during or after anti-angiogeni…
-
CLINICAL_TRIALS trial_result · 2021-09-30Clinical Trial Update: Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors [Phase 1]
Phase 1 study results for INCB001158, an arginase inhibitor, as a single agent and in combination with immune checkpoint therapy, in patient…
-
CLINICAL_TRIALS trial_result · 2021-09-24Clinical Trial Update: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma [Phase 3]
Phase 3 clinical trial update comparing lenvatinib plus everolimus or lenvatinib plus pembrolizumab versus sunitinib alone in advanced renal…